Chronic Myeloid Leukemia News and Research

RSS

Chronic myeloid leukemia (CML) is also known as chronic myelogenous leukemia. According to the American Cancer Society, CML is a type of cancer that starts in blood-forming cells of the bone marrow and then invades the blood. It can spread to the lymph nodes, spleen, liver, and other parts of the body. CML can also change into a fast-growing acute leukemia that invades almost any organ in the body.

Disparities in race, ethnicity, and status affect progress in cancer survival rates in youth

A new study in JNCI Cancer Spectrum finds that dramatic increases in cancer survival in adolescents and young adults are undermined by continuing disparities by race, ethnicity, and socioeconomic status.

12 Jun 2019

Study shows how SIRT1 plays key role in maintaining the regenerative potential of leukemic stem cells

Patients with chronic myeloid leukemia can be treated with tyrosine kinase inhibitors. While these effective drugs lead to deep remission and prolonged survival, primitive leukemia stem cells resist elimination during the remission and persist as a major barrier to cure.

11 Jun 2019

Chemistry researchers patent new method for making anti-leukemia compounds

Chemistry researchers at Oregon State University have patented a method for making anti-leukemia compounds that until now have only been available via an Asian tree that produces them.

21 Mar 2019

Bio-Rad launches new digital PCR system and kit for monitoring treatment response in CML patients

Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad's Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry's first digital PCR products to receive U.S. Food and Drug Administration clearance.

15 Feb 2019

Physicians more likely to prescribe drugs of manufacturers who paid them money

In a study published in The Oncologist, physicians treating certain cancers who consistently received payments from a cancer drug's manufacturer were more likely to prescribe that drug over alternative treatments.

6 Feb 2019

Potential combination therapy against rare disease of the bone marrow could improve treatment

Myelofibrosis is a severe and very rare hematological disease for which treatment has only been partially effective to date. Its low incidence rate is one of the reasons why effective therapies are still lacking.

19 Dec 2018

Research highlights ability of Bio-Rad's ddPCR in quantifying minimal residual disease

More than 30 abstracts presented at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego, December 1-4, featured research highlighting the ability of Bio-Rad's Droplet Digital PCR to provide high sensitivity and accuracy in quantifying minimal residual disease -- those remaining cancer cells after therapy that are associated with relapse -- in blood diseases such as leukemia.

3 Dec 2018

Using molecular targeting approach to kill melanoma cells

In 1960, scientists described the "Philadelphia chromosome" that causes chronic myeloid leukemia, and in 2001 the Food and Drug Administration approved the drug imatinib to disable the action of this cancer-causing genetic change.

27 Nov 2018

Drug combination targets pre-leukemia stem cells

Your body's blood cells are manufactured by hematopoietic stem cells in bone marrow. But just as regular, mature cells can become cancerous, so too can stem cells.

12 Sep 2018

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

30 Aug 2018

OHSU Knight Cancer Institute Director wins 2018 Tang Prize in Biopharmaceutical Science

OHSU Knight Cancer Institute Director Brian J. Druker, M.D., has been awarded the 2018 Tang Prize in Biopharmaceutical Science for his pioneering role in shaping the fields of precision medicine and targeted cancer drugs.

20 Jun 2018

Study: Single surface protein can amplify multiple key pathways in acute myeloid leukemia

Researchers from the Albert Einstein College of Medicine in New York have discovered that a signaling protein elevated in patients with acute myeloid leukemia plays a much wider role in the disease than previously thought.

18 May 2018

Interfering with enzyme's movement may be new approach for developing of anti-cancer drugs

Revealing all the steps required to activate an enzyme called a protein kinase may identify new ways to target cancer, according to new University of Arizona-led research.

16 May 2018

Researchers test new cancer research model that may reduce cost and speed up studies

A new model for improving how clinical trials are developed and conducted by bringing together academic cancer experts and pharmaceutical companies is being tested by research experts at The University of Texas MD Anderson Cancer Center.

15 May 2018

Experts propose new solutions to increase benefit, affordability of targeted cancer medicines

Spending on cancer drugs in the United States has nearly doubled in the past five years and continues to grow, imposing substantial financial burden on patients with cancer.

18 Apr 2018

Study finds link between industry payments and prescription practices for two cancer types

Physicians who received payment from pharmaceutical companies for meals, talks and travel were more likely to prescribe those companies' drugs for two cancer types, a University of North Carolina Lineberger Comprehensive Cancer Center-led study has found.

9 Apr 2018

Novartis announces FDA approval of its first and only CML therapy with TFR data in product label

Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of Treatment-free Remission (TFR) data in the Tasigna® (nilotinib) US product label.

26 Dec 2017

FDA researchers find underrepresentation of adults aged 75 years and older in blood cancer clinical trials

In the first comprehensive analysis of clinical trial enrollment among older adults with blood cancers, researchers from the U.S. Food and Drug Administration found significant gaps in participation among those aged 75 and older when considered against the incidence of these malignancies in this age group, according to research being presented today during the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta.

12 Dec 2017

FDA approved drug found to have anti-cancer activity against previously unknown targets

Developing new drugs to treat cancer can be a painstaking process taking over a decade from start to Food and Drug Administration approval. Scientists are trying to develop innovative strategies to identify and test new drugs quicker and more efficiently.

10 Oct 2017

Existing drugs may be able to improve therapy for chronic myeloid leukemia, mice study shows

Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice.

26 Sep 2017